Novartis India Ltd Falls 10.71%: 3 Key Factors Driving the Weekly Decline

1 June: Record High Followed by Profit-Taking

Novartis India Ltd began the week on a strong note, reaching a new 52-week and all-time high intraday price of Rs.1,588.40. This milestone marked a significant appreciation from its 52-week low of Rs.750.00, reflecting over 111% growth in the past year. However, despite this peak, the stock closed lower at Rs.1,523.60, down 2.05% for the day, as profit-taking emerged after a sustained rally. The broader market was mixed, with the Sensex declining 0.96%, indicating some sector-specific pressures despite the stock’s individual strength.

Technical indicators at this stage remained predominantly bullish, with the stock trading above all major moving averages and positive momentum signals from MACD and Bollinger Bands. Nonetheless, the Relative Strength Index (RSI) suggested short-term overbought conditions, hinting at potential consolidation or pullback.

2 June: Continued Decline Amid Market Divergence

The downward trend intensified on 2 June, with Novartis India Ltd’s share price falling 3.86% to Rs.1,464.85. This decline contrasted with a modest 0.43% gain in the Sensex, highlighting the stock’s underperformance relative to the broader market. Trading volumes decreased to 2,175 shares, suggesting cautious investor sentiment. The stock remained above key longer-term moving averages but slipped below the 5-day average, signalling short-term bearish momentum.

3 June: Sharp Intraday Low Amid Heavy Selling Pressure

On 3 June, Novartis India Ltd faced significant selling pressure, opening with a gap down of 3.01% and hitting an intraday low of Rs.1,360, a 7.16% drop from the previous close. The stock closed at Rs.1,326.20, down 9.47% for the day, markedly underperforming the Sensex which declined 0.34%. This represented the steepest single-day loss of the week and reflected a broader market weakness, with the Sensex trading near its 52-week low.

Despite this sharp decline, the stock remained above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that longer-term technical support levels were intact. However, the breach below the 5-day moving average and bearish monthly RSI suggested short-term momentum had turned negative. The Pharmaceuticals & Biotechnology sector also underperformed, contributing to the stock’s weakness.

4 June: Modest Recovery Supported by Technical Factors

Following the sharp decline, the stock rebounded modestly on 4 June, gaining 1.89% to close at Rs.1,351.20. This recovery was supported by increased volume of 4,639 shares and a slight positive shift in market sentiment, with the Sensex rising 0.19%. The stock’s ability to hold above key moving averages provided some technical support, although the overall trend remained cautious given the recent volatility.

5 June: Further Gains Amid Mixed Market Conditions

Novartis India Ltd extended its recovery on 5 June, rising 2.79% to close at Rs.1,388.90. This marked a second consecutive day of gains, albeit on lower volume of 1,648 shares. The Sensex declined marginally by 0.10%, indicating mixed market conditions. The stock’s resilience in the face of broader market weakness suggests some underlying support, though the weekly performance remained negative overall.

Key Takeaways

Novartis India Ltd’s week was characterised by a sharp reversal after reaching a new all-time high on 1 June. The initial optimism was tempered by profit-taking and broader market weakness, resulting in a 10.71% weekly decline compared to a 0.78% fall in the Sensex. The stock’s underperformance was particularly pronounced midweek, with a 9.47% drop on 3 June amid sectoral and market pressures.

Despite the short-term volatility, the stock remains technically supported above its longer-term moving averages, suggesting that the longer-term uptrend is intact. The recent upgrade in Mojo Grade to ‘Hold’ reflects a balanced view of the company’s prospects, acknowledging both its strong fundamentals and the current market challenges.

Trading volumes showed variability, with a notable spike on the day of the sharp decline, indicating active participation during the sell-off. The stock’s premium valuation metrics and strong capital structure remain positives, though recent quarterly financials showed some softness in profitability, which may have contributed to the cautious sentiment.

Conclusion

Novartis India Ltd’s performance in the week ending 5 June 2026 highlights the challenges of sustaining momentum after significant gains. The stock’s new 52-week and all-time highs early in the week were followed by a marked correction, reflecting profit-taking and broader market headwinds. While the stock’s technical and fundamental profile remains solid, the near-term outlook is clouded by short-term selling pressure and cautious market sentiment.

Investors should monitor the stock’s ability to maintain support levels and watch for confirmation of renewed buying interest. The company’s strong balance sheet and consistent dividend policy provide a foundation for stability, but the recent financial softness and market volatility warrant a measured approach.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →